Articles On Imugene (ASX:IMU)

Imugene (ASX:IMU) has announced a new collaboration under which it will evaluate its CD19 oncolytic virus onCARlytics technology in combination with Eureka Therapeutic’s anti-CD19 ARTEMIS T-cell therapy for the treatment of solid tu...

Today, the S&P/ASX 200 Index (ASX: XJO) kicked off the new week with a green session. At the end of the trading day, the benchmark index finished 0.64% higher at 7,370.8 points. The markets were awash with gains across all sectors exce...

Following Wall Street’s record levels on Friday, the ASX 200 rebounded to rise by 0.6% today. All sectors were in the green, except for Financials which fell by around 0.6%. The sector was dragged down by Westpac (ASX:WBC), which slumped by...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing, the benchmark index is up 0.8% to 7,382.5 points. Four ASX shares that are climbing more than most today are...

Shares in biotech company Imugene Limited (ASX: IMU) are lifting in afternoon trade today and are changing hands 9.09% higher at 54 cents. Imugene’s share price has been gaining ground today after the company announced a strategic partner...

The ASX 200 Health Index (XHJ) is up by 1.30% at the time of writing, compared to the broader index which is higher by 0.5%. The US FDA has accepted the New Drug Application (NDA) for Maxigesic IV, AFT Pharma’s (ASX:AFP) intravenous form of...

Imugene (IMU) teams up with US-based Eureka Therapeutics to test a combination of clinical treatments against solid tumours Imugene will combine its onCARlytics technology with Eureka’s ARTEMIS T-cell therapy and test the products’ ability...

The collaboration has the potential to address the lack of tumour-specific targets in solid tumours for T-cell therapies by using oncolytic virus to force tumours to express CD19.

Today, the S&P/ASX 200 Index (ASX: XJO) slipped lower following in the footsteps of last night’s Wall Street performance. At the end of the session, the benchmark index finished 0.25% lower at 7,430.4 points. It was an underwhelming sh...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Today, the S&P/ASX 200 Index (ASX: XJO) started the week off with a positive move. The benchmark index moved 0.34% higher to 7,441 points. Despite a lagging tech sector, the Aussie benchmark recorded another green day for the year. Pul...

Growing concerns of runaway inflation and a sooner-than-expected rate hiked spooked tech stocks globally. After the tech-heavy NASDAQ fell almost 1% on Friday, the ASX Tech sector was today’s worst performer on the local bourse, down by 0.7...

One of the biggest exploration success stories of the decade prior to COVID-19 was copper play Sandfire Resources (ASX:SFR). A struggling explorer at the time the GFC hit, it stumbled across the DeGrussa copper-gold deposit and is now a $2...

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the City of Hope cancer research and treatment centre has dosed the first patient in the Phase 1 clinical trial of its oncolytic virotherapy candidate....

The odds are stacked against small cap ASX stocks growing into the top echelon of the bourse – the ASX 200 – but it’s possible. Many companies fail due to unexpected hurdles, others are acquired before reaching their full potential. But if...

MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and analysts are looking at right now and in this edition we’re looking at big biotechs. Today we hear from James McDonald, portfolio manager of Pe...

“It’s a proud moment to see CF33-hNIS-antiPDL1 (CHECKvacc) continue its progression and have this Phase I trial underway with patients at City of Hope. While we are starting the oncolytic virus in triple negative breast cancer, given the si...

Imugene (IMU) announced that cancer and research centre, City of Hope, has dosed the first patient in the phase one clinical trial of CHECKvacc The study is recruiting patients with triple negative breast cancer (TNBC), testing the safety...

The ASX 200 posted its second day of steady gains, although the drivers were broadly the reverse of Monday’s session. Falls in resources and financials were offset by a rebound in the tech sector. A day after lagging the market with a fall...

Today, the S&P/ASX 200 Index (ASX: XJO) finished slightly lower after paring earlier gains. The benchmark index moved 0.08% lower to 7,374.9 points. Weakness among the miners put a dent in the strong performance exhibited by tech, heal...

The S&P/ASX 300 Index (ASX: XKO) is climbing in early afternoon trade, after spending the morning in negative territory. At the time of writing, the ASX 300 is up 0.32% to 7,411 points. The index is now in the green for the past month,...

Today, the S&P/ASX 200 Index (ASX: XJO) dealt another day of green to finish the week. The benchmark index climbed 0.69% to 7,362 points. By Friday afternoon the ASX boards were awash with gains. The only sector not pulling its own wei...

The benchmark ASX 200 mounted a last 30-minute rally index to edge just slightly lower on Wednesday, despite choppy trading overnight that saw all major US equity stock indexes fall. The local benchmark finished the day 0.04% lower at 7,277...

The ASX 200 slumped by 0.28%, despite NSW pubs, retail and hairdressers reopening for business. The local bourse followed action on Wall Street last Friday, where markets were down following a worse than expected US employment numbers. Tech...

The market is maintaining its gains today and is up 0.9% so far this week following 4 weeks of losses. Energy stocks are down most following a near 2% fall in oil prices., but despite the decline, the sector is still up 3% this week and was...

Shares in the immunotherapy company Imugene Limited (ASX: IMU) are 7.8% higher in afternoon trade and are now changing hands at 44 cents each. The Imugene share price is gaining ground today despite there being no market-sensitive news fr...

The ASX 200 followed Wall Street lower in Tuesday trade, in line with what looks like the emergence of a broader global trend; buy oil and gold, sell tech. The ASX 200 Energy index is up by around 18% since September 20, and oil & gas s...

The S&P/ASX 200 index (ASX: XJO) has started the week on a downward trend, trading 0.36% lower today at 7251.1 points. At the same time, the S&P/ASX 200 Health Care index (XHJ) has also slipped 0.36% into the red from the opening...

Local markets looked brighter today. US share markets rebounded on Friday. Global oil prices also rose by around 1% on ahead of a meeting of OPEC+ producers today. Analysts expect that producers will add just 400,000 barrels per day in extr...

The S&P/ASX 300 Index (ASX: XKO) is pushing upwards today, recovering lost ground from Friday’s 2% plunge. At the time of writing, the ASX 300 is up 0.98% to 7,260.1 points. It’s worth noting that in the past month, the index has lost...

As we make our way through the first half of FY22, equity markets have begun to shake up somewhat in the last few weeks. The benchmark S&P/ASX 200 Index (ASX: XJO) has slumped almost 4.5% into the red over the last month, back to its...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

The S&P/ASX 300 Index (ASX: XKO) is back in negative territory on Friday, losing ground from yesterday’s strong performance. During mid-afternoon trade, the ASX 300 is down 0.35% to 7,349.3 points. This means that the index is likely t...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Markets were calm and collected on Thursday, as the ASX 200 climbed by more than 1% following a strong lead from Wall Street, and traded with little volatility throughout the session. Investors are still comfortable with the US Fed’s plans...

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced it has received a notice of grant from the Japanese Patent Office for its application to protect its HER-Vaxx immunotherapy.

The Imugene Ltd (ASX: IMU) share price is edging higher in afternoon trade on Wednesday and now trades at 48 cents apiece. That’s a 5.5% gain on the day, well ahead of the S&P/ASX 200 Health Care index which has climbed 0.45%. Imugen...

The S&P/ASX 200 index (ASX: XJO) has spent the day in the green and is currently 0.5% higher at 7,309.7 points. Healthcare shares are amongst the strongest performers leading the broad index’s recovery today, with the S&P/ASX 200...

The company’s HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The ASX 200 lost 0.92% today, taking the benchmark index lower by 0.20% for the week. The local market was trading in the red since the opening bell, with miners hit especially hard. The Mining sector was the worst performer today, falling...

Leader of the ASX health stocks today is Imugene (ASX:IMU) up 4.11% after announcing plans to present its PD1-Vaxx cancer checkpoint immunotherapy program at the ESMO Congress 2021 Annual Meeting in Paris. The company says clinical results...

The S&P/ASX 300 Index (ASX: XKO) is charging higher today following a mixed daily movement throughout the week. At the time of writing, the ASX 300 is up 0.74% to 7,477 points. This means that over the past month, the index is now hove...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

There was broad based selloff across ASX blue chips today, with all 11 sectors falling into the red. The benchmark ASX 200 index ended up lower by 1.9% as it sank further from the mid session loss of 1%. It was one of the biggest drops for...

Highlights The Australian share market is expected to fall again on Thursday after US and European equities witnessed their worst one-day rout in three weeks. The ASX 200 may open the day 27 points or 0.35% lower after falling 0.25% to...

The ASX 200 made a little comeback in afternoon trade, but still traded flat on the day as local stocks struggled for direction. Energy stocks did their best to drag the broader index higher, as oil prices consolidate back above US$70/barre...

The benefit to stock prices on inclusion in the index is significant because all the ETF’s that track or try to emulate the S&P/ASX 300 must take positions and buy stock in the company.

The S&P/ASX 300 Index (ASX: XKO) is in reverse in afternoon trade today. At the time of writing, the ASX 300 is down 0.32% to 7,508 points. Let’s take a look at which ASX companies are leading the charge today. Flight Centre Travel Gr...